Surveillance for Coccidioidomycosis - United States, 2011-2017.


Journal

Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002)
ISSN: 1545-8636
Titre abrégé: MMWR Surveill Summ
Pays: United States
ID NLM: 101142015

Informations de publication

Date de publication:
20 09 2019
Historique:
entrez: 21 9 2019
pubmed: 21 9 2019
medline: 21 3 2020
Statut: epublish

Résumé

Coccidioidomycosis (Valley fever) is an infection caused by the environmental fungus Coccidioides spp., which typically causes respiratory illness but also can lead to disseminated disease. This fungus typically lives in soils in warm, arid regions, including the southwestern United States. 2011-2017. Coccidioidomycosis has been nationally notifiable since 1995 and is reportable in 26 states and the District of Columbia (DC), where laboratories and physicians notify local and state public health departments about possible coccidioidomycosis cases. Health department staff determine which cases qualify as confirmed cases according to the definition established by Council of State and Territorial Epidemiologists and voluntarily submit basic case information to CDC through the National Notifiable Diseases Surveillance System. During 2011-2017, a total of 95,371 coccidioidomycosis cases from 26 states and DC were reported to CDC. The number of cases decreased from 2011 (22,634 cases) to 2014 (8,232 cases) and subsequently increased to 14,364 cases in 2017; >95% of cases were reported from Arizona and California. Reported incidence in Arizona decreased from 261 per 100,000 persons in 2011 to 101 in 2017, whereas California incidence increased from 15.7 to 18.2, and other state incidence rates stayed relatively constant. Patient demographic characteristics were largely consistent with previous years, with an overall predominance among males and among adults aged >60 years in Arizona and adults aged 40-59 years in California. Coccidioidomycosis remains an important national public health problem with a well-established geographic focus. The reasons for the changing trends in reported cases are unclear but might include environmental factors (e.g., temperature and precipitation), surveillance artifacts, land use changes, and changes in the population at risk for the infection. Health care providers should consider a diagnosis of coccidioidomycosis in patients who live or work in or have traveled to areas with known geographic risk for Coccidioides and be aware that those areas might be broader than previously recognized. Coccidioidomycosis surveillance provides important information about the epidemiology of the disease but is incomplete both in terms of geographic coverage and data availability. Expanding surveillance to additional states could help identify emerging areas that pose a risk for locally acquired infections. In Arizona and California, where most cases occur, collecting systematic enhanced data, such as more detailed patient characteristics and disease severity, could help clarify the reasons behind the recent changes in incidence and identify additional opportunities for focused prevention and educational efforts.

Identifiants

pubmed: 31538631
doi: 10.15585/mmwr.ss6807a1
pmc: PMC6756189
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-15

Déclaration de conflit d'intérêts

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Références

Emerg Infect Dis. 2010 Nov;16(11):1738-44
pubmed: 21029532
Pediatr Infect Dis J. 2007 May;26(5):454-6
pubmed: 17468663
Clin Infect Dis. 2013 Mar;56(6):847-50
pubmed: 23223598
Clin Infect Dis. 2016 Sep 15;63(6):e112-46
pubmed: 27470238
Am J Public Health. 2017 Aug;107(8):1296-1303
pubmed: 28640687
Emerg Infect Dis. 2018 Jul;24(8):1444-1452
pubmed: 30014837
Open Forum Infect Dis. 2019 Mar 11;6(3):ofz052
pubmed: 30882015
MMWR Morb Mortal Wkly Rep. 2013 Mar 29;62(12):217-21
pubmed: 23535687
Med Mycol. 2019 Feb 1;57(Supplement_1):S30-S40
pubmed: 30690599
MMWR Morb Mortal Wkly Rep. 2018 Nov 09;67(44):1246-1247
pubmed: 30408020
Emerg Infect Dis. 2018 Apr;24(4):779-781
pubmed: 29553315
Emerg Infect Dis. 2006 Jun;12(6):958-62
pubmed: 16707052
Emerg Infect Dis. 2016 Oct;22(10):1821-3
pubmed: 27649029
MMWR Morb Mortal Wkly Rep. 2017 Aug 11;66(31):833-834
pubmed: 28796756
Emerg Infect Dis. 2018 Mar;24(3):417-423
pubmed: 29460741

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH